Benutzer: Gast  Login
Titel:

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Dokumenttyp:
journal article
Autor(en):
Baigent, C; Landray, MJ; Reith, C; Emberson, J; Wheeler, DC; Tomson, C; Wanner, C; Krane, V; Cass, A; Craig, J; Neal, B; Jiang, L; Hooi, LS; Levin, A; Agodoa, L; Gaziano, M; Kasiske, B; Walker, R; Massy, ZA; Feldt-Rasmussen, B; Krairittichai, U; Ophascharoensuk, V; Fellström, B; Holdaas, H; Tesar, V; Wiecek, A; Grobbee, D; de Zeeuw, D; Grönhagen-Riska, C; Dasgupta, T; Lewis, D; Herrington, W; Mafham, M; Majoni, W; Wallendszus, K; Grimm, R; Pedersen, T; Tobert, J; Armitage, J; Baxter, A; Bray, C;...     »
Abstract:
Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.This randomised double-blind trial included 9270 patients with chronic kidney disease (3023 on dialysis and 6247...     »
Zeitschriftentitel:
Lancet
Jahr:
2011
Band / Volume:
377
Heft / Issue:
9784
Seitenangaben Beitrag:
2181-92
Sprache:
eng
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/21663949
Print-ISSN:
0140-6736
TUM Einrichtung:
Abteilung für Nephrologie
 BibTeX